UPDATE: Citigroup Downgrades ArQule to Neutral, Lowers PT on Increased Uncertainty Around Lead Cancer Drug Candidate

In a report published Wednesday, Citigroup analyst Jonathan Eckard downgraded the rating on ArQule ARQL from Buy to Neutral, and lowered the price target from $5.00 to $2.25. In the report, Citigroup noted, “We are changing our rating on ARQL to Neutral from Buy reflecting the increased uncertainty around the company's lead cancer drug candidate, tivantinib, following a safety signal arising in an ongoing P3 trial for liver cancer. ARQL pipeline is fairly deep and includes other late-stage tivantinib trials, and several wholly-owned early-stage agents. However, this new uncertainty around tivantinib clouds the timelines of what was already a ‘longer-term story'. We are moving to the sidelines until additional clarity is available regarding the potential for their P3 liver cancer trial to continue.” ArQule closed on Tuesday at $2.19.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorDowngradesAnalyst RatingsCitigroupJonathan Eckard
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!